Article
Oncology
Shannon Stockton, Paul Catalano, Steven J. Cohen, Barbara A. Burtness, Edith P. Mitchell, Efrat Dotan, Sam J. Lubner, Pankaj Kumar, Mary F. Mulcahy, George A. Fisher, Theodore L. Crandall, Al Benson
Summary: This randomized phase II trial compared the efficacy of paclitaxel (arm A) and paclitaxel plus cixutumumab (arm B) as second-line therapy for patients with metastatic esophageal or gastroesophageal junction cancers. The results showed that the addition of cixutumumab to paclitaxel did not significantly improve clinical outcomes, including progression-free survival and overall survival, compared to standard of care. Therefore, cixutumumab did not show enhanced efficacy when combined with paclitaxel in the treatment of metastatic esophageal/GEJ cancer.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This trial evaluated the safety and efficacy of ipatasertib in combination with different chemotherapy regimens for metastatic triple-negative breast cancer (mTNBC). The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and the overall response rates and progression-free survival varied among the different treatment arms. Further study is needed to better understand the role of AKT inhibition in the treatment of TNBCs.
Article
Oncology
Yuan Yuan, Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Daniel Schmolze, James Waisman, Niki Patel, Lalit Vora, Lusine Tumyan, Mari Bozoghlanian, Daphne Stewart, Paul H. Frankel
Summary: This study evaluated the safety and efficacy of ipatasertib in combination with carboplatin, carboplatin/paclitaxel, or capecitabine/atezolizumab in patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoints were safety and recommended phase II dose (RP2D), while secondary endpoints included progression-free survival (PFS), response rate, and overall survival. The results showed that continuous dosing of ipatasertib with chemotherapy was safe and well-tolerated, and further research is needed to understand the role of AKT inhibition in the treatment of TNBC.
Article
Oncology
David H. Johnson, Louis Fehrenbacher, William F. Novotny, Roy S. Herbst, John J. Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore III, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz Kabbinavar
Summary: This study aimed to investigate the efficacy and safety of bevacizumab in combination with carboplatin and paclitaxel for advanced or recurrent non-small-cell lung cancer. The results showed that the addition of bevacizumab improved overall response and time to progression, but bleeding was the most prominent adverse event. Patients with nonsquamous cell histology appeared to have better treatment outcomes and acceptable safety risks.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
M. Usman Ahmad, Christopher Javadi, George A. Poultsides
Summary: Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection and locoregional control for resectable proximal gastric, gastroesophageal junction, and distal esophageal cancer. Treatment recommendations differ based on histologic type and tumor location. Neoadjuvant chemoradiation with concurrent taxane- or fluoropyrimidine-based chemotherapy has shown efficacy for both adenocarcinoma and squamous cell carcinoma of the distal esophagus and gastroesophageal junction.
Review
Biotechnology & Applied Microbiology
Suhana Ahmad, Lidawani Lambuk, Naveed Ahmed, Ali Mussa, Vincent Tee, Ros Akmal Mohd Idris, Nur Fazimah Sahran, Yean Yean Chan, Rosline Hassan, Yeong Yeh Lee, Rohimah Mohamud
Summary: Nab-paclitaxel demonstrates good efficacy and safety in the treatment of metastatic gastric cancer, providing better disease response and longer survival.
Review
Oncology
Changsu Lawrence Park, Charles Vincent Rajadurai, Tuyet Nhung Ton Nu, Victoria Mandilaras
Summary: Colorectal carcinosarcoma is a rare subtype of colorectal cancer with both mesenchymal and epithelial tumor features. This report describes the successful treatment of a 76-year-old woman with metastatic colorectal carcinosarcoma using carboplatin and paclitaxel, which has not been previously reported. Previous case reports of this disease have shown aggressive behavior and poor response to systemic treatments. Further studies are needed to validate this treatment regimen and assess long-term outcomes.
Article
Oncology
Stefano Cascinu, Gyorgy Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Gunnar Folprecht, Sumitra Ananda, Gustavo Girotto, Zev A. Wainberg, Maria Luisa Limon Miron, Jaffer Ajani, Ran Wei, Astra M. Liepa, Roberto Carlesi, Michael Emig, Atsushi Ohtsu
Summary: In the RAINBOW study, ramucirumab plus paclitaxel showed higher objective response rate than the control arm in previously treated advanced gastric or gastroesophageal junction adenocarcinoma patients, with longer response duration, leading to improved quality of life.
Article
Oncology
Qingling Jiang, Hong Qian, Lin Mei, Qi Sun, Xiaofei Cheng, Wenzhi Huang, Minglin Xia, Jia Shao, Jidong Wang
Summary: This study aimed to investigate the efficacy of bevacizumab, paclitaxel, and carboplatin in the treatment of ovarian cancer and their impact on patients' prognosis. The results showed that the combination treatment significantly improved the objective remission rate, disease control rate, and reduced the levels of CA199, CEA, and CA242 without increasing the incidence of adverse events.
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
(2022)
Article
Oncology
Di Maria Jiang, Hao-Wen Sim, Osvaldo Espin-Garcia, Bryan A. Chan, Akina Natori, Charles H. Lim, Stephanie Moignard, Eric X. Chen, Geoffrey Liu, Gail Darling, Carol J. Swallow, Savtaj Brar, James Brierley, Jolie Ringash, Rebecca Wong, John Kim, Patrik Rogalla, Sara Hafezi-Bakhtiari, Jennifer J. Knox, Raymond W. Jang, Elena Elimova
Summary: A retrospective study found similar outcomes between using CP and CF in TMT for esophageal or GEJ cancer patients, but CF may be a superior regimen in the setting of dCRT.
Article
Oncology
Karen Mulder, Howard Lim, Deepti Ravi, Shahida Ahmed, Bryan Brunet, Janine Davies, Corinne Doll, Dorie-Anna Dueck, Vallerie Gordon, Pamela Hebbard, Christina A. Kim, Duc Le, Richard Lee-Ying, John Paul McGhie, Jason Park, Daniel J. Renouf, Devin Schellenberg, Ralph P. W. Wong, Adnan Zaidi, Shahid Ahmed
Summary: Immunotherapy is increasingly recognized as playing an important role in the treatment of gastro-esophageal cancer, with experts from the Western Canadian Gastrointestinal Cancer Consensus Conference giving high attention to its role.
Article
Oncology
Yusuf Ilhan, Ali Murat Tatli, Fatih Teker, Arif Hakan Onder, Fatih Kose, Caglayan Geredeli, Mustafa Karaagac, Muhammet Ali Kaplan, Mevlude Inanc, Sabin Goktas Aydin, Aysegul Kargi, Haci Arak, Banu Ozturk, Ali Ayberk Besen, Oguzhan Selvi, Mustafa Korkmaz, Zeynep Oruc, Oktay Bozkurt, Ahmet Bilici, Selami Bayram, Shute Ailia Dae, Mustafa Ozdogan, Hasan Senol Coskun, Sema Sezgin Goksu
Summary: There is no difference in survival between cisplatin or carboplatin combined with paclitaxel and bevacizumab in the treatment of metastatic or recurrent cervical cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Medicine, General & Internal
Yin Tao, Xue-Ting Tang, Xing Li, An-Shan Wu, Hou-Shen Zhou, Cheng-fang Zhou
Summary: This study evaluated the role of neoadjuvant chemotherapy (NACT) with intraperitoneal perfusion of bevacizumab in advanced ovarian cancer. The results showed that treatment with the TCB regimen significantly reduced serum levels of CA125 and ascites volume, as well as intraoperative blood loss and operation time. Patients treated with the TCB regimen had a higher surgical satisfaction rate, and a lower incidence of postoperative complications compared with the TC group. No severe complications were observed between the two groups during chemotherapy.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Wenwu He, Xuefeng Leng, Tianqin Mao, Xi Luo, Lingxiao Zhou, Jiaxin Yan, Lin Peng, Qiang Fang, Guangyuan Liu, Xing Wei, Kangning Wang, Chenghao Wang, Sha Zhang, Xudong Zhang, Xudong Shen, Depei Huang, Huan Yi, Ting Bei, Xueke She, Wenguang Xiao, Yongtao Han
Summary: This study focuses on locally advanced resectable esophageal squamous cell carcinoma (ESCC), investigating the safety, feasibility, and efficacy of neoadjuvant toripalimab plus paclitaxel and carboplatin treatment. The results indicate that this combination therapy shows potential as a neoadjuvant treatment for ESCC, with increased CD8(+) T cells and decreased M2-type tumor-associated macrophages in responders. Furthermore, certain molecular signatures were associated with treatment response.
Article
Oncology
Ivonne Haffner, Katrin Schierle, Elba Raimundez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele Siegler, Stefan Fuxius, Thomas Decker, Christian Wittekind, Florian Lordick
Summary: Discrepancies in HER2 assessment in mGC were found in tumor specimens with intermediate HER2 expression. Borderline HER2 positivity and heterogeneity of HER2 expression should be considered as resistance factors for HER2-targeting treatment of mGC. HER2 thresholds should be reconsidered.
JOURNAL OF CLINICAL ONCOLOGY
(2021)